Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

180 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Implant-associated primary anaplastic large-cell lymphoma with simultaneous involvement of bilateral breast capsules.
Bautista-Quach MA, Nademanee A, Weisenburger DD, Chen W, Kim YS. Bautista-Quach MA, et al. Clin Breast Cancer. 2013 Dec;13(6):492-5. doi: 10.1016/j.clbc.2013.08.009. Clin Breast Cancer. 2013. PMID: 24267734 No abstract available.
Approach to Hodgkin's lymphoma in the new millennium.
Fung HC, Nademanee AP. Fung HC, et al. Hematol Oncol. 2002 Mar;20(1):1-15. doi: 10.1002/hon.683. Hematol Oncol. 2002. PMID: 11921013 Review.
To improve the overall outcome of patients with Hodgkin's lymphoma, future studies need to focus on reducing the therapy-related toxicity for patients with good risk disease as well as improving disease control for patients with poor risk disease through a risk-adapted app …
To improve the overall outcome of patients with Hodgkin's lymphoma, future studies need to focus on reducing the therapy-related toxicity fo …
A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma.
Nademanee A, Forman S, Molina A, Fung H, Smith D, Dagis A, Kwok C, Yamauchi D, Anderson AL, Falk P, Krishnan A, Kirschbaum M, Kogut N, Nakamura R, O'donnell M, Parker P, Popplewell L, Pullarkat V, Rodriguez R, Sahebi F, Smith E, Snyder D, Stein A, Spielberger R, Zain J, White C, Raubitschek A. Nademanee A, et al. Blood. 2005 Oct 15;106(8):2896-902. doi: 10.1182/blood-2005-03-1310. Epub 2005 Jul 7. Blood. 2005. PMID: 16002426 Free PMC article. Clinical Trial.
Patients underwent dosimetry (day -21) with 5 mCi (185 MBq) 111In-ibritumomab tiuxetan following 250 mg/m2 rituximab, followed a week later by 90Y-ibritumomab tiuxetan to deliver a target dose of 1000 cGy to highest normal organ. ...At a median follow-up of 2 …
Patients underwent dosimetry (day -21) with 5 mCi (185 MBq) 111In-ibritumomab tiuxetan following 250 mg/m2 rituximab, followed a week …
Longitudinal assessment of hematopoietic abnormalities after autologous hematopoietic cell transplantation for lymphoma.
Bhatia R, Van Heijzen K, Palmer A, Komiya A, Slovak ML, Chang KL, Fung H, Krishnan A, Molina A, Nademanee A, O'Donnell M, Popplewell L, Rodriguez R, Forman SJ, Bhatia S. Bhatia R, et al. J Clin Oncol. 2005 Sep 20;23(27):6699-711. doi: 10.1200/JCO.2005.10.330. J Clin Oncol. 2005. PMID: 16170178
RESULTS: A significant reduction in primitive and committed progenitors was observed before HCT compared with healthy controls. ...Extended follow-up of a larger number of patients is required to confirm whether alterations in progenitor and telomere recovery predic …
RESULTS: A significant reduction in primitive and committed progenitors was observed before HCT compared with healthy controls. ...Ex …
Does follicularity in large cell lymphoma predict outcome after autologous stem cell transplantation?
Krishnan A, Nademanee A, Fung H, Angelopoulou M, Molina A, Gaal K, Dagis A, Palmer J, Alvarnas J, Slovak M, Kogut N, Popplewell L, Rodriguez R, Schriber J, Wang S, Forman SJ. Krishnan A, et al. Biol Blood Marrow Transplant. 2006 Jun;12(6):641-7. doi: 10.1016/j.bbmt.2005.12.040. Biol Blood Marrow Transplant. 2006. PMID: 16737937
Although ASCT is a potentially curative treatment for patients with recurrent DLCL, the effectiveness of this approach in patients with FLCL is unclear. We undertook a retrospective analysis of 332 patients with large cell lymphoma who underwent ASCT at the City of …
Although ASCT is a potentially curative treatment for patients with recurrent DLCL, the effectiveness of this approach in patients wi …
Role of hematopoietic stem cell transplantation for advanced-stage diffuse large cell B-cell lymphoma-B.
Nademanee A, Forman SJ. Nademanee A, et al. Semin Hematol. 2006 Oct;43(4):240-50. doi: 10.1053/j.seminhematol.2006.07.006. Semin Hematol. 2006. PMID: 17027658 Review.
The outcomes of transplant are better in patients with chemosensitive relapse: those with a longer duration of first remission (>12 month) and those with an age-adjusted low-risk International Prognostic Index (IPI) at relapse. ...
The outcomes of transplant are better in patients with chemosensitive relapse: those with a longer duration of first remission (>1 …
Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma.
Rodriguez R, Nademanee A, Ruel N, Smith E, Krishnan A, Popplewell L, Zain J, Patane K, Kogut N, Nakamura R, Sarkodee-Adoo C, Forman SJ. Rodriguez R, et al. Biol Blood Marrow Transplant. 2006 Dec;12(12):1326-34. doi: 10.1016/j.bbmt.2006.08.035. Biol Blood Marrow Transplant. 2006. PMID: 17162215
We performed a retrospective analysis of 88 patients conditioned with conventional myeloablative regimens (CMRs) (n = 48) and an RIR (n = 40) of fludarabine 125 mg/m(2) and melphalan 140 mg/m(2). ...Using a Cox univariate proportional hazards model, we found that ch …
We performed a retrospective analysis of 88 patients conditioned with conventional myeloablative regimens (CMRs) (n = 48) and an RIR …
Tandem autologous stem cell transplantation for patients with primary refractory or poor risk recurrent Hodgkin lymphoma.
Fung HC, Stiff P, Schriber J, Toor A, Smith E, Rodriguez T, Krishnan A, Molina A, Smith D, Ivers B, Kogut N, Popplewell L, Rodriguez R, Somlo G, Forman SJ, Nademanee A. Fung HC, et al. Biol Blood Marrow Transplant. 2007 May;13(5):594-600. doi: 10.1016/j.bbmt.2007.01.072. Epub 2007 Mar 23. Biol Blood Marrow Transplant. 2007. PMID: 17448919 Clinical Trial.
We conducted a pilot study to evaluate the toxicities and efficacy of a tandem transplant approach in this subgroup of patients. ...After a median of 64 days (25-105), 41 patients received the second ASCT. With a median follow-up of 5.3 years (1.6-8.1) …
We conducted a pilot study to evaluate the toxicities and efficacy of a tandem transplant approach in this subgroup of patient …
Peripheral blood hematopoietic stem cell mobilization and collection efficacy is not an independent prognostic factor for autologous stem cell transplantation.
Wang S, Nademanee A, Qian D, Dagis A, Park HS, Fridey J, Smith E, Snyder D, Somlo G, Stein A, Rosenthal J, Falk P, Kogut N, Palmer J, Gaal K, Kim Y, Bhatia R, Yuan S, Kay C, Weiss L, Forman S. Wang S, et al. Transfusion. 2007 Dec;47(12):2207-16. doi: 10.1111/j.1537-2995.2007.01448.x. Epub 2007 Aug 21. Transfusion. 2007. PMID: 17714420
BACKGROUND: The successful mobilization and collection of hematopoietic stem cells are dependent on a number of clinical factors such as previous chemotherapy and disease stage. ...All patients underwent stem cell collection until a target or a minimum CD34+ …
BACKGROUND: The successful mobilization and collection of hematopoietic stem cells are dependent on a number of clinical factors such …
180 results
Jump to page
Feedback